Stockreport

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B [Yahoo! Finance]

Precision BioSciences, Inc.  (DTIL) 
Last precision biosciences, inc. earnings: 11/12 07:15 am Check Earnings Report
PDF Clinical trial applications submitted for the first gene editing approach for chronic hepatitis B Final clinical candidate safety data and plans for the Phase 1 trial [Read more]